Other

Remainder of Fiscal Year 2024

Royalty Pharma Remainder of Fiscal Year 2024 increased by 200.8% to $3.04M in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ1 2020
Last reportedQ1 2026
Metric ID: remainder_2024

Historical Data

3 periods
 Q2 '25Q3 '25Q1 '26
Value$2.02M$1.01M$3.04M
QoQ Change—-49.9%+200.8%
Range$1.01M – $3.04M

Remainder of Fiscal Year 2024 at Other Companies

Viatris logo
ViatrisVTRSView metric
Biogen logo
BiogenBIIBView metric
Amgen logo
AmgenAMGNView metric

Frequently Asked Questions

What is Royalty Pharma's remainder of fiscal year 2024?
Royalty Pharma (RPRX) reported remainder of fiscal year 2024 of $3.04M in Q1 2026.